Serological biomarkers PRO-C3 and PRO-C6 reveal the anti-fibrotic and pro-metabolic effects of MSDC-0602K, an insulin sensitizer, in non-alcoholic steatohepatitis patients during the EMMINENCE phase IIb study

azemiglitazone (MSDC-0602K) - Cirius Therap

Alejandro Mayorca Guiliani1; Peder Frederiksen1; Morten Karsdal1; Diana Leeming1; Jerry Colca2

Apr 13, 2023